Helus Pharma Inc. (HELP) P/E Ratio History
Insufficient DataInsufficient historical P/E data to classify valuation. · Data 2026–2026
Loading P/E history...
P/E Ratio Analysis
As of November 8, 2026, Helus Pharma Inc. (HELP) trades at a price-to-earnings ratio of -2.6x, with a stock price of $8.96 and trailing twelve-month earnings per share of $-3.50.
Relative to the broader market, HELP trades at a notable discount to the S&P 500 median P/E of 21.8x. Investors should consider the company's growth prospects, competitive position, and earnings quality when evaluating whether the current valuation is justified.
For a comprehensive intrinsic value estimate using discounted cash flow analysis, see our HELP DCF Valuation Calculator →
Note: P/E ratio is just one valuation metric. It does not account for balance sheet strength, cash flow quality, or growth sustainability. Always conduct comprehensive due diligence before making investment decisions.
HELP Cross-Benchmark Valuation
How does the current P/E compare to sector peers and the broader market?
HELP P/E vs Peers
Closest public peers sorted by market cap
| Company | Market Cap | P/E Ratio | PEG Ratio | EPS Growth (1Y) |
|---|---|---|---|---|
| $12B | 26.2 | 1.14 | -25% | |
| $31M | 15.0 | - | -77% | |
| $1B | 7.1Lowest | 0.69Best | +817%Best | |
| $4B | 10.3 | - | +68% |
Lower P/E can signal a discount or weaker growth expectations; PEG adds growth context.
HELP Chart Terminal
Live VCP patterns, Cup & Handle overlays, support/resistance, and AI trade plans.
Live Breakouts Feed
High-probability breakout stocks crossing their pivot across 5 pattern engines.
Intrinsic Valuation
DCF models, multiple analysis, and analyst estimates.
Historical Returns
10-year return with dividends reinvested.
Peer Comparison
Compare growth, multiples, and margins vs sector.
HELP — Frequently Asked Questions
Quick answers to the most common questions about buying HELP stock.
What is HELP's P/E ratio?
Helus Pharma Inc. (HELP) trailing twelve-month P/E ratio is -2.6x, based on TTM diluted EPS of $-3.50. The 5-year average P/E is N/A and the historical range spans N/A to N/A.
Is HELP stock overvalued or undervalued?
HELP current P/E: -2.6x. 5-year average P/E: N/A. Percentile: N/A.
Is HELP stock expensive?
HELP is fairly valued relative to its own history. The current P/E of -2.6x is near the 5-year average of N/A (N/A percentile of historical range).
What is HELP's historical P/E range?
Over the past 5 years, HELP's P/E ratio has ranged from N/A to N/A, with a median of N/A and an average of N/A. The current P/E of -2.6x places the stock at the N/A percentile of this range. Full historical data spans 2026–2026.
How does HELP's P/E compare to the S&P 500?
HELP trades at -2.6x P/E versus the S&P 500 median of 21.8x. The 112% discount to the market suggests lower growth expectations or perceived higher risk.
How does HELP's valuation compare to sector peers?
Helus Pharma Inc. P/E of -2.6x can be benchmarked against sector peers in the comparison table on this page.
What is HELP's PEG ratio?
HELP PEG ratio is N/A, based on a P/E of -2.6x and EPS growth of 24.3%. PEG normalises P/E by growth and helps compare stocks with different earnings trajectories.
What is HELP's earnings yield?
HELP earnings yield is N/A, the inverse of its -2.6x P/E ratio. Earnings yield represents the percentage of each dollar invested that the company earns. It can be compared directly to bond yields to assess relative attractiveness of stocks versus fixed income.